ONE YEAR FOLLOW-UP OF PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE U300 IN CLINICAL PRACTICE

被引：0
|
作者：
Bramlage, P. [1 ]
Lanzinger, S. [2 ]
Danne, T. [3 ]
Muehldorfer, S. [4 ]
Hess, G. M.
Naudorf, M. [5 ]
Holl, R. [2 ]
机构：
[1] Inst Pharmacol & Prevent Med, Mahlow, Germany
[2] Univ Ulm, Inst Epidemiol & Med Biometry ZIBMT, Ulm, Germany
[3] Childrens Hosp, BULT Diabetol Endocrinol Gastroenterol & Clin Res, Hannover, Germany
[4] Klinikum Bayreuth GmbH, Gastroenterol Clin, Bayreuth, Germany
[5] Diabet Ctr Lindlar, Med Practice, Lindlar, Germany
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
095
引用
收藏
页码：A43 / A43
页数：1
相关论文
共 50 条
  • [21] Current Issues: Insulin Substitution with Toujeo((R)) (Insulin Glargine U300) in geriatric Patients with Type-2-Diabetes - guideline conformal and practice-oriented
    Fasching, P.
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2016, 9 (01): : 26 - 28
  • [22] Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes
    Porcellati, Francesca
    Lucidi, Paola
    Candeloro, Paola
    Cioli, Patrizia
    Andreoli, Anna Marinelli
    Curti, Gianluca
    Bolli, Geremia B.
    Fanelli, Carmine G.
    DIABETES CARE, 2019, 42 (01) : 85 - 92
  • [23] New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus
    Goldman, Jennifer
    White, John R., Jr.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (10) : 1153 - 1161
  • [24] Euglycemic Clamp Profile of New Insulin Glargine U300 Formulation in Patients With Type 1 Diabetes (T1DM) Is Different from Glargine U100
    Tillner, Joachim
    Bergmann, Karin
    Teichert, Lenore
    Dahmen, Raphael
    Heise, Tim
    Becker, Reinhard H. A.
    DIABETES, 2013, 62 : A234 - A234
  • [25] More Consistent Antilipolitic and Antiketogenetic Action of Insulin Glargine U300 vs. U100 in Type 1 Diabetes
    Lucidi, Paola
    Candeloro, Paola
    Andreoli, Anna Marinelli
    Cioli, Patrizia
    Bolli, Geremia B.
    Fanelli, Carmine G.
    Porcellati, Francesca
    DIABETES, 2017, 66 : A270 - A270
  • [26] Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
    Yuji Kawaguchi
    Jun Sawa
    Chie Hamai
    Yasuro Kumeda
    Diabetes Therapy, 2019, 10 : 1535 - 1541
  • [27] Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
    Kawaguchi, Yuji
    Sawa, Jun
    Hamai, Chie
    Kumeda, Yasuro
    DIABETES THERAPY, 2019, 10 (04) : 1535 - 1541
  • [28] More physiological circulating insulin and modulation of hepatic glucose production with insulin Glargine U300 vs U100 in type 1 diabetes
    Porcellati, F.
    Lucidi, P.
    Andreoli, A. Marinelli
    Cioli, P.
    Candeloro, P.
    Bolli, G. B.
    Fanelli, C. G.
    DIABETOLOGIA, 2017, 60 : S307 - S308
  • [29] Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naive Patients with Type 2 Diabetes Mellitus: DosInGlar Study
    Duque, Natalia
    Artime, Esther
    Romera, Irene
    Lebrec, Jeremie
    Diaz, Silvia
    Rubio, Miriam
    Sicras-Mainar, Antoni
    Carretero-Anibarro, Enrique
    Mundet, Xavier
    Gorgojo-Martinez, Juan J.
    Reviriego, Jesus
    ADVANCES IN THERAPY, 2021, 38 (07) : 3857 - 3871
  • [30] 7-year Simulation of Clinical Outcomes In People With Type 2 Diabetes Treated With Insulin Glargine 300 U/mL vs 100 U/mL
    Shao, H.
    Shi, L.
    Fonseca, V.
    Alsaleh, A. J. O.
    Gill, J.
    Charlie, N.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
12345